Biomissile registers BM230-PD-1 trial for HER2 tumors, an untested pairing
The Phase Ib/II study is the first industry trial to combine BM230 with a PD-1 inhibitor across eight HER2-linked solid tumors, entering a target field otherwise led by antibody-drug conjugates.
Executive Summary
- Biomissile is testing its HER2-targeted candidate in combination with a PD-1 inhibitor for the first time, layering checkpoint blockade onto a mechanism it is already studying alone.
- The study spans multiple HER2-linked tumor types in patients who have already failed standard treatment, reflecting a broad hypothesis-testing approach rather than a single indication bet.
- The combination enters a HER2 field already led by antibody-drug conjugates in later-stage testing, positioning BM230 as an earlier-stage entrant testing a different combination approach rather than a first-in-class mechanism.
- The trial has not started enrolling, so the near-term news is operational: whether recruitment begins on schedule and what the dose-escalation portion shows about tolerability before any efficacy signal is assessed.
The trial
The newly registered study, NCT07698587, will test BM230 alongside a PD-1 inhibitor in patients with HER2-expressing tumors who have progressed on prior therapy, spanning colorectal cancer, esophageal squamous cell carcinoma, urothelial carcinoma, cholangiocarcinoma, endometrial cancer, cervical cancer, ovarian cancer, and other solid tumors. The trial targets 90 patients across second-line-and-later and third-line-and-later populations, is listed as not yet recruiting, and carries a start date of July 1, 2026, with a primary completion date of December 1, 2029. The sponsor is Suzhou Biomissile Pharmaceuticals Co., Ltd., a China-based industry sponsor running the study exclusively at sites in China. NCT07698587A Phase Ib/II Study of BM230 in Combination With PD-1 Inhibitor for HER2-related Advanced Solid TumorsNCT07698587
What the trial will test
The registered primary outcomes cover dose-limiting toxicity and maximum tolerated dose or recommended Phase II dose in the Ib portion, alongside best overall response, disease control rate, objective response rate, duration of response, progression-free survival, and overall survival assessed by RECIST 1.1 across expansion cohorts. That structure is typical of a combination dose-finding study feeding into tumor-type-specific expansion cohorts: the early read will be tolerability of pairing BM230 with checkpoint blockade, not efficacy, and any response signal will come only after the recommended dose is set. NCT07698587A Phase Ib/II Study of BM230 in Combination With PD-1 Inhibitor for HER2-related Advanced Solid TumorsNCT07698587
Where BM230 stands
BM230 is already being tested alone in a recruiting Phase 1 trial spanning solid tumors, breast cancer, gastric cancer, colorectal cancer, and non-small cell lung cancer, targeting 123 patients with a primary completion date of December 2027. The new combination study runs alongside that monotherapy program rather than replacing it, indicating the sponsor is pursuing both single-agent and combination paths for the same HER2-targeted candidate.
The competitive field
No industry trial currently pairs a HER2-targeted agent with a PD-1 inhibitor across this specific set of HER2-related indications, but the broader HER2 field is active: Daiichi Sankyo's trastuzumab deruxtecan is in Phase 3 testing in endometrial cancer, and Shanghai JMT-Bio's anbenitamab and Sichuan Baili's BL-M07D1 are both in Phase 3 in breast cancer, with these leading HER2 programs predominantly antibody-drug conjugates rather than checkpoint-inhibitor combinations. HER2-targeted trial activity overall has slowed, with 354 recent trials against 2,695 older ones, a decline that reflects the field's maturity around established modalities rather than around BM230's specific combination approach.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.